Market Cap : 58.33 M | Enterprise Value : 58.49 M | PE Ratio : At Loss | PB Ratio : 1.47 |
---|
NAS:ORGS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ORGS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return-on-Tangible-Equity is calculated as Net Income attributable to Common Stockholders divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Orgenesis's annualized net income attributable to common stockholders for the quarter that ended in Dec. 2021 was $-20.06 Mil. Orgenesis's average shareholder tangible equity for the quarter that ended in Dec. 2021 was $20.45 Mil. Therefore, Orgenesis's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2021 was -98.11%.
The historical rank and industry rank for Orgenesis's Return-on-Tangible-Equity or its related term are showing as below:
During the past 13 years, Orgenesis's highest Return-on-Tangible-Equity was 44.58%. The lowest was -73.57%. And the median was -14.50%.
ORGS's Return-on-Tangible-Equity is ranked worse thanThe historical data trend for Orgenesis's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Orgenesis's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Orgenesis's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Orgenesis's Return-on-Tangible-Equity falls into.
Orgenesis's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2021 is calculated as
Return-on-Tangible-Equity | = | Net Income attributable to Common Stockholders | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(A: Dec. 2021 ) | (A: Dec. 2020 ) | (A: Dec. 2021 ) | |||||
= | Net Income attributable to Common Stockholders | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets ) | / count ) | |
(A: Dec. 2021 ) | (A: Dec. 2020 ) | (A: Dec. 2021 ) | |||||
= | -18.053 | / | ( (30.811 | + | 18.264 ) | / 2 ) | |
= | -18.053 | / | 24.5375 | ||||
= | -73.57 % |
Orgenesis's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2021 is calculated as
Return-on-Tangible-Equity | = | Net Income attributable to Common Stockholders | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(Q: Dec. 2021 ) | (Q: Sep. 2021 ) | (Q: Dec. 2021 ) | |||||
= | Net Income attributable to Common Stockholders | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets) | / count ) | |
(Q: Dec. 2021 ) | (Q: Sep. 2021 ) | (Q: Dec. 2021 ) | |||||
= | -20.064 | / | ( (22.638 | + | 18.264) | / 2 ) | |
= | -20.064 | / | 20.451 | ||||
= | -98.11 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income attributable to common stockholders of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Dec. 2021) net income attributable to common stockholders data. Return-on-Tangible-Equity is displayed in the 10-year financial page.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Net income attributable to common stockholders is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Thank you for viewing the detailed overview of Orgenesis's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Sidransky David | director | JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205 |
Reithinger Neil | officer: CFO, Treasurer and Secretary | 14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260 |
Philips Mario | director | C/O ATMI, INC DANBURY CT 06810 |
Ferber Sarah | officer: Chief Scientific Officer | 17B HAHASKALA STREET TEL AVIV L3 67890 |
Yachin Guy | director | 7 ORCHARD WAY N POTOMAC MD 20854 |
Nanda Ashish | director | 2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452 |
Bedoret Denis | officer: See Remarks | 48, RUE AUGUSTE PICCARD GOSSELIES C9 6041 |
Universite Libre De Bruxelles | other: less than 10% | AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050 |
Theodorus Ii Sa | other: less than 10% | ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070 |
Theodorus Sca | other: less than 10% | ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070 |
Belenger Olivier | other: less than 10% | DIEWEG, 69 BRUSSELS C9 1070 |
Shvartz Oded | 10 percent owner | 130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000 |
Bultot Hugues | director | AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150 |
Buyse Chris Georges Frans | director | BAILLET LATOURLEI 119A BRUSSELS C9 2390 |
Tenne Joseph | officer: CFO Treasurer Secretary | 6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511 |
From GuruFocus
By Marketwired 06-29-2020
Other Sources
By Seekingalpha 2021-11-06